RFA
RIGL icon

Reilly Financial Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Reilly Financial Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-20
Closed – – 951
2016
Q4 		$0 Buy
+20
New +$573 ﹤0.01% 889

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Reilly Financial Advisors's RIGL Position: Q1 2017 in Review

Reilly Financial Advisors sold out of Rigel Pharmaceuticals (RIGL) in Q1 2017, closing a stake of 20 shares.

Reilly Financial Advisors first reported a position in RIGL in Q4 2016 and held it in 1 quarter. The position peaked at $0 in Q4 2016. 99 funds tracked by Wall St. Rank hold RIGL as of Q1 2017.

  • Reilly Financial Advisors reported no remaining Rigel Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Reilly Financial Advisors sold 20 Rigel Pharmaceuticals shares in Q1 2017.
  • Reilly Financial Advisors first reported a position in Rigel Pharmaceuticals in Q4 2016 and held it in 1 quarter.
  • Reilly Financial Advisors's Rigel Pharmaceuticals position peaked at $0 in Q4 2016.
  • 99 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2017.

Based on Reilly Financial Advisors's 13F filing for Q1 2017, filed 18 Apr 2017.